Oxford Drug Design receives over £8m in grant and equity investment

Matthew | June 18, 2019

Oxford Drug Design announced today success in securing funds, totalling over £8m, from CARB-X, the UK Department of Health and Social Care Small Business Research Initiative (SBRI) and equity investment led by o2h Ventures.

The funds will be used to advance their dual-target aminoacy-tRNA synthetase inhibitor (DaaRSi) project, which is developing new antibiotics effective against drug-resistant ‘Superbugs’ and to continue development of their proprietry machine learning platform to tackle other valuable pharmaceutical targets.

CARB-X, the world’s largest public-private partnership focused on funding the advancement of Gram-negative antibiotics, has agreed to back the DaaRSi project with a milestone dependent, non-dilutive, award for over £5m. This will be further accelerated by an award of £2M from the DHSC SBRI funding stream and equity investment led by o2h Ventures, which launched Britain’s first therapeutics and AI fund earlier this year.

Photo by Holger Link on Unsplash

Get the top featured stories in your e-mail and don’t ever miss out on important news.